Daporinad

• CAT Number: I011889
• CAS Number: 658084-64-1
• Molecular Formula: C24H29N3O2
• Molecular Weight: 391.51
• Purity: ≥95%
• Synonyms: APO866; APO-866; APO 866; FK 866; FK-866; FK866; Daporinad;(E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
• Solubility: Soluble in DMSO, not in water
• Storage: Store at 0-8 °C
• IUPAC Name: (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide
• InChI: InChI=1S/C24H29N3O2/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28)/b12-11+
• InChIKey: KPBNHDGDUADAGP-VAWYXSNFSA-N
• SMILES: C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3

Daporinad（Cat No.:I011889）, also known as FK866, is a selective inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). By inhibiting NAMPT, daporinad reduces NAD+ levels, which disrupts cellular energy metabolism and induces cell death, particularly in cancer cells. This makes daporinad a promising candidate for cancer therapy, as many cancer cells are highly dependent on NAD+ for survival. It has also shown potential in treating other conditions, including neurodegenerative diseases, where NAD+ depletion could help prevent neuronal damage. Clinical trials are ongoing to evaluate its safety and efficacy.